REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases.  "2026 is set to be a transformative ...

True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...

Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's first "prototype" for a CRISPR therapy, based on technology invented at UC ...

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for ...

Research about LENN -- a patent-pending, virus-mimicking platform technology that targets bladder cancer cells with mRNA ...

If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...